



Cornerstone Pharmaceuticals, Inc
1 Duncan Drive
Cranbury, NJ 08512

Media Contact: Meghan Weber
Liza Sullivan & Associates
(917) 399-8713

LEADING ONCOLOGIST DR. ROBERT SHEPARD JOINS CORNERSTONE PHARMACEUTICALS AS ACTING CHIEF MEDICAL OFFICER

Cranbury, NJ, November 4, 2009 – Cornerstone Pharmaceuticals, Inc., a privately-held pharmaceutical company, announced that esteemed cancer drug developer and oncologist, Robert C. Shepard, M.D., F.A.C.P. has joined the company as its acting Chief Medical Officer (CMO). With nearly 40 years of experience in cancer research, Dr. Shepard will play a major role in the ongoing clinical development of CPI-613 and other drug candidates; CPI-613 is the first drug emerging from the company's Altered Energy Metabolism Directed (AEMD) technology platform and pipeline.

"On behalf of our staff and management, I am very pleased to welcome Dr. Robert Shepard to Cornerstone Pharmaceuticals," remarked Dr. Robert Shorr, Chief Executive Officer for Cornerstone Pharmaceuticals. "Dr. Shepard's vast experience and skills are a wonderful compliment to our team and an asset to our various clinical programs."

Dr. Shepard has extensive experience and expertise in the clinical research and development of cancer drugs. Dr. Shepard graduated Magna cum Laude in Biochemical Sciences and Molecular Biophysics from Harvard College, followed by a year in the Harvard-M.I.T. Health Sciences Program, and later earned his MD degree in the Medical Scientist Training M.D.-Ph.D. Program at Duke University School of Medicine which included two years in graduate school studying immunology.

His fellowship training, in both hematology and oncology, was done at Tufts-New England Medical Center and the Dana-Farber Cancer Center, both in Boston, followed by a post-doctorate fellowship in Pharmacology and Molecular Genetics at Harvard Medical School. Dr. Shepard completed his medical internship at Memorial Sloan Kettering Cancer Center in New York City. Additionally, Dr. Shepard was also a Medical Officer at the Center for Biologics Evaluation and Research at the U.S. Food and Drug Administration and was involved in the medical review of Avastin and Erbitux as well as other New Molecular Entity drugs (NMEs).

"I am very excited to join Cornerstone Pharmaceuticals, particularly during what is a very exciting time for the company," commented Dr. Shepard. "I am also looking forward to working with their world-class management and R&D professionals, all of whom are regarded as top innovators and leaders in their fields."



Dr. Shepard has extensively published in peer-reviewed literature, and was study co-chair for numerous Eastern Cooperative Oncology Group (ECOG) clinical trials in myeloma as well as in breast cancer and gastrointestinal cancers. Together with Dr. Robert Kyle, Dr. Shepard served as co-chair of the ECOG Myeloma Committee from 1985 to 2002. More recently, Dr. Shepard has been responsible for the complete clinical development of several drugs and immune therapies for several companies and has served as the Principal Investigator for drugs being developed by companies including Pfizer, Astra Zeneca, Merck, Bristol Myers, Schering, Novartis, Lilly, Glaxo and Roche. Dr. Shepard is board-certified in hematology and internal medicine, and holds full-time academic appointments at Harvard University, Tufts University and the University of Virginia and part-time posts at Johns Hopkins University, the University of North Carolina and Duke University.

About CPI-613

CPI-613 is the first drug in a new chemical class that, through a novel mechanism, targets metabolic changes that may be common to many cancer types. Cornerstone Pharmaceuticals is currently recruiting patients with solid tumors to advance multiple Phase I/II human clinical trials of CPI-613, CPI-613 is being evaluated in a Phase I/II single agent trial for patients who have failed all other therapy as well as in a Phase I/II combination trial with gemcitabine in newly diagnosed or relapsed patients determined to be treated with gemcitabine. Pancreatic cancer, like many solid tumors, typically has a poor prognosis, spreads rapidly and often goes undetected in its early stages. CPI-613 has been granted orphan drug status by the US FDA for pancreatic cancer.

About Cornerstone Pharmaceuticals

Cornerstone Pharmaceuticals, Inc. is a privately held company that is committed to changing the way cancer is treated through the discovery and development of innovative therapies capitalizing on the unique metabolic processes of cancer cells. The company's founding members, management and scientific advisory team include pre-eminent scientists focused on cancer cell metabolism, cancer research and drug development. Cornerstone is the only company that currently has a drug in clinical trials targeting certain key enzymes crucial to cancer cell metabolism. The company's unique approach to targeting cancer metabolism has led to the discovery of first-in-class drugs with the potential to transform the way cancer is treated. Its lead drug, CPI-613, is currently being evaluated in three ongoing Phase I and Phase I/II clinical trials in a variety of tumor types. For further information, visit <http://www.cornerstonepharma.com>. Or contact: Meghan Weber at (917) 399-8713.

#

This release contains forward-looking statements. These statements relate to future events or each company's future financial performance. In some cases, you can identify forward-looking statements by terminology such as "may", "will", "should", "expect", "plan", "anticipate", "believe", "estimate", "predict", "potential" or "continue", the negative of such terms, or other comparable terminology. These statements are only predictions. Actual events or results may differ materially from those in the forward-looking statements as a result of various important factors. Although we believe that the expectations reflected in the forward-looking statements are reasonable, such statements should not be regarded as a representation by the company, or any other person, that such forwardlooking statements will be achieved. The business and operations of the company are subject to substantial risks



which increase the uncertainty inherent in forward-looking statements. We undertake no duty to update any of the forward-looking statements, whether as a result of new information, future events or otherwise. In light of the foregoing, readers are cautioned not to place undue reliance on such forward-looking statements.